JMT101 and liposomal mitoxantrone for nasopharyngeal cancer
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This study tests a new combination of two drugs (JMT101 and a liposomal form of mitoxantrone) for people with nasopharyngeal cancer that has not responded to standard treatments like immune therapy and chemotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your nasopharyngeal cancer has not responded to or has returned after immune therapy (a PD-1/PD-L1 checkpoint inhibitor) and at least two chemotherapy treatments, including a platinum-based chemo.
- You have at least one tumor on a scan that can be measured and has not been treated with radiation, or it has clearly grown after radiation.
- You are able to take care of yourself and are not bedridden (a score of 0 or 1 on the ECOG scale).
- Your blood counts, liver, kidney, and clotting tests are within acceptable levels, and you have not had a transfusion or growth factor injection within 14 days.
- If you can become pregnant, you must agree to use highly effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a chemotherapy drug (mitoxantrone liposome) with an immunotherapy (PD-1 blocker) for people whose nasopharyngeal cancer has come back or spread and hasn't responded to previous treatments. The goal is to see if this combination can shrink tumors or slow cancer growth.
This trial is testing whether adding a new form of chemotherapy (mitoxantrone hydrochloride liposome injection) to capecitabine (a standard chemotherapy pill) helps people with advanced nasopharyngeal carcinoma live longer or control their cancer better than capecitabine alone. You may be eligible if your cancer has progressed after platinum-based chemotherapy.
This trial tests a new form of chemotherapy (liposomal mitoxantrone) for children, adolescents, and young adults whose solid tumors have come back or not responded to treatment. The goal is to see if this combination regimen can help shrink tumors.
This trial tests a new drug combination for a type of lung cancer called squamous non-small cell lung cancer. It aims to see if the combination can help people whose cancer has grown after standard treatments.
This trial tests a new drug called TMT101 for people with advanced pancreatic cancer or non-small cell lung cancer who have already tried other treatments. The goal is to see if TMT101 is safe and works against the cancer.
This trial tests a new combination of immunotherapy (JS001) and chemotherapy (PFLL) versus a standard regimen (GP) for people with nasopharyngeal cancer that has spread. The goal is to see if the new combination works better at controlling the disease.
Hear when a new Recurrent or Metastatic Nasopharyngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.